Enanta Pharmaceuticals (ENTA) Tax Provisions (2014 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Tax Provisions came in at $7000.0 in Q1 2026, up 100.54% YoY from $3490.6 in Q1 2025, and down 70.83% on a QoQ basis from $24000.0 in Q4 2025.
Enanta Pharmaceuticals (ENTA) Tax Provisions (2014 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 13 years of Tax Provisions data on file, last reported at $7000.0 in Q1 2026.
- Quarterly Tax Provisions rose 100.54% year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92000.0 (up 103.71% YoY) and the FY2025 annual result came in at -$1.7 million, up 4.76% from the prior year.
- Tax Provisions fell to $7000.0 in Q1 2026, from $24000.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $4.2 million in Q2 2023 to a low of -$3.9 million in Q3 2023.
- A 5-year average of -$219125.0 and a median of -$198500.0 in 2022 frame the typical range for Tax Provisions.
- The widest YoY moves for Tax Provisions: up 1044.3% in 2023, down 28185.71% in 2023.
- Tracing ENTA's Tax Provisions over 5 years: stood at -$34000.0 in 2022, then tumbled by 1729.41% to -$622000.0 in 2023, then jumped by 33.12% to -$416000.0 in 2024, then jumped by 105.77% to $24000.0 in 2025, then slumped by 70.83% to $7000.0 in 2026.
- The last three Tax Provisions figures came in at $7000.0 (Q1 2026), $24000.0 (Q4 2025), and $32000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 36,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36,000.00 |
| Mar 31, 2026 | 7,000.00 |
| Dec 31, 2025 | 24,000.00 |
| Sep 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Mar 31, 2025 | -1.31 Mn |
| Dec 31, 2024 | -416,000.00 |
| Sep 30, 2024 | -363,000.00 |
| Jun 30, 2024 | -395,000.00 |
| Mar 31, 2024 | -363,000.00 |
| Dec 31, 2023 | -622,000.00 |
| Sep 30, 2023 | -3.93 Mn |
| Jun 30, 2023 | 4.22 Mn |
| Mar 31, 2023 | 44,000.00 |
| Dec 31, 2022 | -34,000.00 |
| Sep 30, 2022 | 14,000.00 |
| Jun 30, 2022 | -447,000.00 |
| Dec 31, 2021 | -36,000.00 |
| Sep 30, 2021 | 48.51 Mn |
| Jun 30, 2021 | -9.38 Mn |